Cardiol Therapeutics (CRDL) CEO to discuss MAVERIC, ARCHER and CRD-38 in X interview

Rhea-AI Filing Summary

Cardiol Therapeutics Inc. filed a report highlighting a live interview where its CEO will discuss key clinical programs. The session on X, hosted by Barchart, will cover the pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis, recent Phase II ARCHER results in acute myocarditis, and the Company’s next-generation heart failure candidate CRD-38. The filing also reiterates that Cardiol is a late-stage life sciences company developing anti-inflammatory and anti-fibrotic therapies for serious heart diseases, with CardiolRx™ granted U.S. FDA Orphan Drug Designation for pericarditis.

Key Figures

Interview time: 12:00 p.m. EDT MAVERIC trial phase: Phase III ARCHER study phase: Phase II +1 more

4 metrics

Interview time 12:00 p.m. EDT Live X interview with Barchart on April 14, 2026

MAVERIC trial phase Phase III Ongoing pivotal MAVERIC trial of CardiolRx™ in recurrent pericarditis

ARCHER study phase Phase II Completed ARCHER study of CardiolRx™ in acute myocarditis

Heart failure U.S. healthcare costs US$30 billion per year Associated healthcare costs for heart failure in the United States

Key Terms

Orphan Drug Designation, recurrent pericarditis, acute myocarditis, fulminant heart failure, +1 more

5 terms

Orphan Drug Designation regulatory

"The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

recurrent pericarditis medical

"The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis"

Inflammation of the thin sac around the heart that comes back after a first episode. Like a door that keeps sticking shut even after being fixed, recurrent pericarditis involves repeated bouts of chest pain, fever, or fatigue that can require ongoing treatment, tests, or even procedures. Investors track it because recurrent disease affects healthcare spending, drug trial design, regulatory review, and the potential market for therapies aimed at preventing or managing flare-ups.

acute myocarditis medical

"The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis"

Acute myocarditis is a sudden inflammation of the heart muscle that can weaken the heart’s ability to pump and cause irregular rhythms, often requiring medical treatment or hospitalization. For investors, it matters because cases can affect employee or executive health, trigger product safety or clinical-trial concerns, increase medical and legal costs, and prompt regulatory scrutiny—similar to how a jammed pump can slow down an entire factory’s output and raise repair bills.

fulminant heart failure medical

"an important cause of acute and fulminant heart failure in young adults"

forward-looking information regulatory

"This news release contains "forward-looking information" within the meaning of applicable securities laws"

Forward-looking information are predictions, plans, estimates or expectations about a company’s future performance, results or events, such as sales forecasts, project timelines, or anticipated costs. It matters to investors because these statements guide expectations but rely on assumptions and uncertain factors—like a weather forecast for a business—so investors should treat them as informed guesses rather than guarantees and consider the risks and possible changes behind the numbers.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Accepted by SEC EDGAR 04/14/2026 - 07:29 AM Learn about SEC filing dates

FAQ

What did Cardiol Therapeutics (CRDL) announce in this Form 6-K filing?

Cardiol Therapeutics announced a live interview on X where its CEO will discuss the Phase III MAVERIC trial, Phase II ARCHER results, and the CRD-38 heart failure program, alongside reiterating its focus on therapies for inflammatory heart disease.

What is Cardiol Therapeutics’ MAVERIC Phase III trial mentioned for CRDL?

The MAVERIC Program evaluates CardiolRx™ for recurrent pericarditis, an inflammatory disease of the pericardium causing chest pain, shortness of breath, and fatigue. It includes the completed Phase II MAvERIC-Pilot study and the ongoing pivotal Phase III MAVERIC trial in this patient population.

What were the ARCHER Phase II trial results Cardiol (CRDL) plans to discuss?

The ARCHER Program studied CardiolRx™ in acute myocarditis, a cause of acute and fulminant heart failure in young adults. The completed Phase II ARCHER study evaluated safety, tolerability, and efficacy, and recently published results will be discussed during the live Barchart interview.

What is CRD-38 in Cardiol Therapeutics’ (CRDL) pipeline?

CRD-38 is a novel, subcutaneously administered drug formulation in development for inflammatory heart disease, including heart failure. Heart failure is a leading cause of death and hospitalization, with associated U.S. healthcare costs exceeding US$30 billion per year, underscoring its medical relevance.

When and where is Cardiol Therapeutics’ Barchart interview taking place?

The interview is scheduled for April 14, 2026 at 12:00 p.m. EDT on X. It will be hosted on Barchart’s @Barchart account, with a recording available afterward on Cardiol’s @CardiolRx channel and Barchart’s account.

What regulatory status does CardiolRx™ have for pericarditis treatment?

CardiolRx™ has received U.S. FDA Orphan Drug Designation for the treatment of pericarditis, including recurrent pericarditis. This designation recognizes the condition as a rare disease and can provide certain development and commercialization incentives for the company.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-40712

Cardiol Therapeutics Inc.
(Translation of registrant's name into English)

602-2265 Upper Middle Road East, Oakville, Ontario, Canada L6H 0G5
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

[   ] Form 20-F     [X] Form 40-F

SUBMITTED HEREWITH

Exhibits

Exhibit		Description
99.1		News Release dated April 14, 2026 - Cardiol Therapeutics to Highlight MAVERIC Phase III Trial and Recently Published ARCHER Results in Live Interview with Barchart

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CARDIOL THERAPEUTICS INC.
	(Registrant)
Date: April 14, 2026	By:	/s/ Chris Waddick
		Chris Waddick
	Title:	Chief Financial Officer

Cardiol Therapeutics to Highlight MAVERIC Phase III Trial
and Recently Published ARCHER Results in Live Interview with Barchart

Toronto, ON - April 14, 2026 - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, is pleased to announce that Cardiol's President and Chief Executive Officer, David Elsley, will participate in a live interview on X with Barchart.com ("Barchart") today at 12:00 p.m. EDT.

Interview Topics:

• The ongoing pivotal Phase III MAVERIC trial of CardiolRx™ in recurrent pericarditis
• Results from the recently published Phase II ARCHER trial of CardiolRx™ in acute myocarditis
• The Company's next generation drug, CRD-38, in development for heart failure

Interview details:

Date: April 14, 2026
Time: 12:00 PM EDT
Platform: X
Host Account on X: @Barchart
Join Live Interview at: x.com/Barchart

After the event, a full recording of the interview will be available on the Company's X channel (@CardiolRx) and Barchart's (@Barchart).

About Cardiol Therapeutics

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. The Company's lead small-molecule drug candidate, CardiolRx™, modulates inflammasome pathway activation, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with pericarditis, myocarditis, and heart failure.

The MAVERIC Program is evaluating CardiolRx™ for the treatment of recurrent pericarditis, an inflammatory disease of the pericardium associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, which can lead to physical limitations, reduced quality of life, emergency department visits, and hospitalizations. The program comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing pivotal Phase III MAVERIC trial (NCT06708299). The U.S. FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, including recurrent pericarditis.

The ARCHER Program is also studying CardiolRx™, specifically in acute myocarditis–an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in individuals under 35 years of age. The program comprises the completed Phase II ARCHER study (NCT05180240), which evaluated the safety, tolerability, and efficacy of CardiolRx™ in this patient population.

The Company is also developing CRD-38, a novel, subcutaneously administered drug formulation intended for the treatment of inflammatory heart disease, including heart failure–a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding US$30 billion per year.

For more information about Cardiol Therapeutics, please visit cardiolrx.com.

Cautionary statement regarding forward-looking information:

This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward-looking information contained herein may include, but is not limited to statements regarding the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease; the Company's intended clinical studies and trial activities and timelines associated with such activities, including the Company's plan to complete the Phase III study in recurrent pericarditis with CardiolRx™; the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation intended for the treatment of inflammatory heart disease, including heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Information Form filed with the Canadian securities administrators and U.S. Securities and Exchange Commission on March 31, 2026, available on SEDAR+ at sedarplus.ca and EDGAR at sec.gov, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise. Investors are cautioned not to rely on these forward-looking statements.

For further information, please contact:

Investor.relations@cardiolrx.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 8.2 KB